Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04910048
Other study ID # 262790
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 17, 2022
Est. completion date December 23, 2024

Study information

Verified date October 2023
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this pilot study, we will test the hypothesis that a POPOP for currently ineligible UAMS orthopedic surgery patients wanting hip or knee replacement improves markers of preoperative health, ability to reach a BMI threshold <40 kg/m2 required for surgical eligibility, and postoperative outcomes versus SOC.


Description:

After being informed about the study and potential risks, all patients giving written informed consent will be screened to determine eligibility for study entry. Patients who meet eligibility criteria will be randomized into one of two groups: Standard of Care or the POPOP (20Lighter).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 46
Est. completion date December 23, 2024
Est. primary completion date April 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - End-stage knee or hip osteoarthritis, avascular necrosis, or rheumatoid arthritis with recommended primary, unilateral total joint arthroplasty by orthopaedic surgeons at the University of Arkansas for Medical Sciences (Jeffrey Stambough, Dr. C. Lowry Barnes, Dr. Simon Mears, and Dr. Benjamin Stronach) - BMI between 41.00-48.00 kg/m2 at time of enrollment - Over the age of 18 years - Would consider undergoing a total joint arthroplasty if eligible - Owns a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection - Willing to comply with the requirements of the study and provide informed consent prior to enrollment. Exclusion Criteria: - Patients with a BMI less than 41.00 or greater than 48.00 - Pregnancy - Breastfeeding - History of a major organ transplant or other health issue requiring immunosuppressant drugs - Strict vegetarian diet - Diagnosis of and/or are taking medication for psychiatric conditions including schizophrenia, bipolar disorder or manic depression - Patients scheduled for, or those who have previously undergone, bariatric surgery - Patients unable to understand and speak English - Patients requiring a revision or bilateral TJA - Patients unwilling or unable to use a bluetooth-enabled smartphone with cell service or home internet access - Incarceration

Study Design


Intervention

Other:
POPOP (preoperative patient optimization program)
A 2 month structured program focused on reduction of BMI, body weight, visceral fat, body fat and improvement of lean body mass and intracellular fluid.
SOC (standard of care)
Referral to a dietician for two months of self-directed weight loss

Locations

Country Name City State
United States UAMS Orthopaedic Clinic - Shackleford Little Rock Arkansas

Sponsors (1)

Lead Sponsor Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

References & Publications (10)

Bolognesi MP, Marchant MH Jr, Viens NA, Cook C, Pietrobon R, Vail TP. The impact of diabetes on perioperative patient outcomes after total hip and total knee arthroplasty in the United States. J Arthroplasty. 2008 Sep;23(6 Suppl 1):92-8. doi: 10.1016/j.arth.2008.05.012. — View Citation

Boyce L, Prasad A, Barrett M, Dawson-Bowling S, Millington S, Hanna SA, Achan P. The outcomes of total knee arthroplasty in morbidly obese patients: a systematic review of the literature. Arch Orthop Trauma Surg. 2019 Apr;139(4):553-560. doi: 10.1007/s00402-019-03127-5. Epub 2019 Feb 16. — View Citation

Gerlach E, Selley R, Johnson D, Nicolay R, Versteeg G, Plantz M, Tjong V, Terry M. Patient-Reported Outcomes Measurement Information System Validation in Hip Arthroscopy: A Shift Towards Reducing Survey Burden. Cureus. 2021 Feb 10;13(2):e13265. doi: 10.7759/cureus.13265. — View Citation

Goodman SM, Mehta BY, Mandl LA, Szymonifka JD, Finik J, Figgie MP, Navarro-Millan IY, Bostrom MP, Parks ML, Padgett DE, McLawhorn AS, Antao VC, Yates AJ, Springer BD, Lyman SL, Singh JA. Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials. J Arthroplasty. 2020 May;35(5):1200-1207.e4. doi: 10.1016/j.arth.2019.12.038. Epub 2019 Dec 27. — View Citation

Harold RE, Butler BA, Delagrammaticas D, Sullivan R, Stover M, Manning DW. Patient-Reported Outcomes Measurement Information System Correlates With Modified Harris Hip Score in Total Hip Arthroplasty. Orthopedics. 2021 Jan 1;44(1):e19-e25. doi: 10.3928/01477447-20201202-02. Epub 2020 Dec 7. — View Citation

Horn ME, Reinke EK, Couce LJ, Reeve BB, Ledbetter L, George SZ. Reporting and utilization of Patient-Reported Outcomes Measurement Information System(R) (PROMIS(R)) measures in orthopedic research and practice: a systematic review. J Orthop Surg Res. 2020 Nov 23;15(1):553. doi: 10.1186/s13018-020-02068-9. — View Citation

Keeney BJ, Austin DC, Jevsevar DS. Preoperative Weight Loss for Morbidly Obese Patients Undergoing Total Knee Arthroplasty: Determining the Necessary Amount. J Bone Joint Surg Am. 2019 Aug 21;101(16):1440-1450. doi: 10.2106/JBJS.18.01136. — View Citation

Lingamfelter M, Orozco FR, Beck CN, Harrer MF, Post ZD, Ong AC, Ponzio DY. Nutritional Counseling Program for Morbidly Obese Patients Enables Weight Optimization for Safe Total Joint Arthroplasty. Orthopedics. 2020 Jul 1;43(4):e316-e322. doi: 10.3928/01477447-20200521-08. Epub 2020 Jun 5. — View Citation

Shaka H, Ojemolon PE. Impact of Obesity on Outcomes of Patients With Hip Osteoarthritis Who Underwent Hip Arthroplasty. Cureus. 2020 Oct 10;12(10):e10876. doi: 10.7759/cureus.10876. — View Citation

Shapiro JA, Narayanan AS, Taylor PR, Olcott CW, Del Gaizo DJ. Fate of the Morbidly Obese Patient Who Is Denied Total Joint Arthroplasty. J Arthroplasty. 2020 Jun;35(6S):S124-S128. doi: 10.1016/j.arth.2020.01.071. Epub 2020 Feb 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of patients converting from ineligible to eligible status Assessment of the percentage of patients achieving a BMI of 40.0 kg/m2 or less in each treatment group Approximately 70-110 days from study enrollment
Other Percentage of patients who proceed to TJA Assessment of the percentage of patients that undergo TJA in each treatment group Approximately 110-120 days from study enrollment
Other Change of PROMs in the 6-weeks after knee replacement Assessment of change in the patient reported outcomes survey KOOS Jr, for patients undergoing knee replacement Approximately 180 days from study enrollment (or 6 weeks after TJA)
Other Change of PROMs in the 6-weeks after hip replacement Assessment of change in the patient reported outcomes survey HOOS Jr, for patients undergoing hip replacement Approximately 180 days from study enrollment (or 6 weeks after TJA)
Other Change of PROMIS Pain Interference in the 6-weeks after joint replacement Assessment of change in PROMIS Pain Interference patient reported outcome instrument Approximately 180 days from study enrollment (or 6 weeks after TJA)
Other Change of PROMIS Physical Function in the 6-weeks after joint replacement Assessment of change in PROMIS Physical Function patient reported outcome instrument Approximately 180 days from study enrollment (or 6 weeks after TJA)
Other All-cause complication rate at 30-days post TJA Rate of surgical complications requiring hospital readmission, ER or acute care visit in 30 days after TJA Approximately 160 days from study enrollment (or 30 days after TJA)
Other All-cause complication rate at 60-days post TJA Rate of surgical complications requiring hospital readmission, ER or acute care visit in 60 days after TJA Approximately 190 days from study enrollment (or 60 days after TJA)
Other All-cause complication rate at 90-days post TJA Rate of surgical complications requiring hospital readmission, ER or acute care visit in 90 days after TJA Approximately 220 days from study enrollment (or 90 days after TJA)
Primary Change of pre-operative BMI Assessment of mean change in BMI (Body Mass Index, kg/m2) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of red blood cell count Change of values in red blood cells as assessed by (Complete Blood Count) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of white blood cell count Change of values in white blood cells as assessed by CBC (Complete Blood Count) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of platelet count Change of values in platelets as assessed by CBC (Complete Blood Count) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of albumin Change of values in Albumin as assessed by CMP (Comprehensive Metabolic Panel) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of ALT (alanine aminotransferase) Change of values in ALT (alanine aminotransferase) as assessed by CMP (Comprehensive Metabolic Panel) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of AST (aspartate aminotransferase) Change of values in AST (aspartate aminotransferase) as assessed by CMP (Comprehensive Metabolic Panel) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Pre-operative health & nutritional status as assessed by change of BUN (blood urea nitrogen) Change of values in BUN (blood urea nitrogen) as assessed by CMP (Comprehensive Metabolic Panel) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative health & nutritional status as assessed by Creatinine Change of values in Creatinine as assessed by CMP (Comprehensive Metabolic Panel) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative type 2 diabetes as assessed by HbA1c (Hemaglobin A1c) laboratory test values Assessment of change in HbA1c (Hemaglobin A1c) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative inflammation as assessed by CRP (C-Reactive Protein) laboratory test values Assessment of change in CRP (C-Reactive Protein) between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative PROMs (Knee Replacement) Assessment of change in the patient reported outcomes survey KOOS Jr, knee replacement patients between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative PROMs (Hip Replacement) Assessment of change in the patient reported outcomes survey HOOS Jr, hip replacement patients between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative PROMIS Pain Interference Assessment of change in PROMIS Pain Interference patient reported outcome instrument between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
Secondary Change of pre-operative PROMIS Physical Function Assessment of change in PROMIS Physical Function patient reported outcome instrument between the date of enrollment to follow-up visit to occur between days 70-110 Approximately 70-110 days from study enrollment
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4